Serine

Serine

SCHEMBL1064689

NCC(=O)OC(=O)CN.N[C@@H](CO)C(=O)O

nearest known ligand 0.43

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC1A1 P43005 5/20 0.43
PTGS1 P23219 1/20 0.39
SLC7A11 Q9UPY5 1/20 0.39
GSR P00390 2/20 0.39
GRIK1 P39086 3/20 0.37
SLC1A3 P43003 3/20 0.37
SLC1A2 P43004 3/20 0.37
GRIK2 Q13002 2/20 0.37
GRM1 Q13255 2/20 0.37
GRM2 Q14416 2/20 0.37
GRIA4 P48058 2/20 0.37
GRIK3 Q13003 2/20 0.37
GRIK5 Q16478 2/20 0.37
SLC7A5 Q01650 1/20 0.37
GRM8 O00222 1/20 0.37
GRM6 O15303 1/20 0.37
GRIN2D O15399 1/20 0.37
GRIN3B O60391 1/20 0.37
CYP1A2 P05177 1/20 0.37
GRM5 P41594 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Serine SCHEMBL3628164 0.96 SLC1A1 (0.41) SLC1A1PTGS1SLC7A11GSRGRIK1
Serine SCHEMBL12500509 0.96 SLC1A1 (0.41) SLC1A1PTGS1SLC7A11GSRGRIK1
Serine SCHEMBL17792546 0.89 SLC1A1 (0.47) SLC1A1GSRGRIK1SLC1A3SLC1A2
Asparagine SCHEMBL7563049 0.89 SLC1A1 (0.40) SLC1A1PTGS1SLC7A11GSRGRIK1
Serine SCHEMBL15094110 0.86 SLC1A5 (0.38) SLC1A1PTGS1SLC7A11GSRGRIK1
Serine SCHEMBL3052910 0.86 SLC1A5 (0.35) SLC1A1PTGS1SLC7A11GSR
Serine SCHEMBL3821533 0.86 SLC1A5 (0.38) SLC1A1PTGS1SLC7A11GSRGRIK1
Serine SCHEMBL6568300 0.86 SLC1A1 (0.34) SLC1A1PTGS1SLC7A11GSRGRIK1
SCHEMBL1072689 0.85 SLC1A5 (0.36) SLC1A1PTGS1SLC7A11GSRGRIK1
Serine SCHEMBL6666261 0.85 SLC7A5 (0.38) SLC1A1PTGS1SLC7A11GSRGRIK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 261 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4355886-A1 RETINAL DISORDERS Ikarovec Limited (GB) 2024-04-24 EP claimed
EP-4355767-A1 RETINAL DISORDERS Ikarovec Limited (GB) 2024-04-24 EP claimed
EP-4355789-A2 TNFSF-L FUSION PROTEINS AND USES THEREOF KaliVir Immunotherapeutics, Inc. (US) 2024-04-24 EP claimed
EP-3283124-B1 BIOCONJUGATES AND USES THEREOF SYMIC HOLDINGS USA INC (US) 2024-04-24 EP claimed
CN-117916274-A TNFSF-L fusion proteins and uses thereof 卡利威尔免疫治疗公司 2024-04-19 CN claimed
CN-117897493-A Retinal disorders 伊卡罗维克有限公司 2024-04-16 CN claimed
CN-117813321-A Retinal disorders 伊卡罗维克有限公司 2024-04-02 CN claimed
EP-4151647-A1 AMINO ACID SEQUENCE OF RECOMBINANT TICK-BORNE ENCEPHALITIS VIRUS-LIKE PARTICLES AND THEIR USE AS A VACCINE ANTIGEN FOR PREVENTION OF TICK-BORNE ENCEPHALITIS VIRUS INFECTIONS University of Gdansk (PL) 2023-03-22 EP claimed
WO-2022263841-A1 RETINAL DISORDERS Ikarovec Limited (GB) 2022-12-22 WO claimed
WO-2022266163-A2 TNFSF-L FUSION PROTEINS AND USES THEREOF KALIVIR IMMUNOTHERAPEUTICS, INC. (US) 2022-12-22 WO claimed
WO-2019010490-A1 BICONJUGATES WITH CHEMICALLY MODIFIED BACKBONES SYMIC IP, LLC (US) 2019-01-10 WO claimed
CN-107771085-A Bioconjugates and application thereof 斯米克IP有限公司 2018-03-06 CN claimed
EP-3283124-A1 BIOCONJUGATES AND USES THEREOF Symic IP, LLC (US) 2018-02-21 EP claimed
WO-2017132332-A1 CHIMERIC HEPATITIS D VIRUS ANTIGEN AND HEPATITIS B VIRUS PRE S1 GENES FOR USE ALONE OR IN VACCINES CONTANING HEPATITIS B VIRUS GENES SVENSKA VACCINFABRIKEN PRODUKTION AB (SE) 2017-08-03 WO claimed
US-20170112941-A1 VE-CADHERIN BINDING BIOCONJUGATE SYMIC IP, LLC 2017-04-27 US claimed
US-20160331841-A1 BIOCONJUGATES AND USES THEREOF SYMIC IP, LLC 2016-11-17 US claimed
WO-2016168743-A1 BIOCONJUGATES AND USES THEREOF SYMIC IP, LLC (US) 2016-10-20 WO claimed
US-20160228531-A1 TREATMENT OF HEPATITIS D VIRUS INFECTIONS BY REDIRECTION OF T CELLS CHRONTECH PHARMA AB (SE) 2016-08-11 US claimed
EP-3046936-A1 TREATMENT OF HEPATITIS D VIRUS INFECTIONS BY REDIRECTION OF T CELLS ChronTech Pharma AB (SE) 2016-07-27 EP claimed
WO-2015042187-A1 TREATMENT OF HEPATITIS D VIRUS INFECTIONS BY REDIRECTION OF T CELLS CHRONTECH PHARMA AB (SE) 2015-03-26 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160331841-A1 BIOCONJUGATES AND USES THEREOF CD44, VCAM1, ICAM1 SLC1A1 1192/4885PTGS1 2460/4885SLC7A11 789/4885
US-20170112941-A1 VE-CADHERIN BINDING BIOCONJUGATE EPCAM, CDH1, VCAM1 SLC1A1 1342/4885PTGS1 4543/4885SLC7A11 1066/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.